As of 2025-07-01, the Intrinsic Value of Hollister Biosciences Inc (HOLL.CN) is 0.19 CAD. This HOLL.CN valuation is based on the model Discounted Cash Flows (EBITDA Exit 5Y). With the current market price of 0.15 CAD, the upside of Hollister Biosciences Inc is 31.30%.
The range of the Intrinsic Value is 0.14 - 0.24 CAD
Based on its market price of 0.15 CAD and our intrinsic valuation, Hollister Biosciences Inc (HOLL.CN) is undervalued by 31.30%.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (0.10) - (0.05) | (0.06) | -141.7% |
| DCF (Growth 10y) | (0.04) - (0.08) | (0.05) | -135.1% |
| DCF (EBITDA 5y) | 0.14 - 0.24 | 0.19 | 31.3% |
| DCF (EBITDA 10y) | 0.18 - 0.36 | 0.26 | 80.4% |
| Fair Value | 0.08 - 0.08 | 0.08 | -43.88% |
| P/E | 0.01 - 0.04 | 0.02 | -88.5% |
| EV/EBITDA | 0.96 - 1.88 | 1.38 | 848.8% |
| EPV | (0.23) - (0.34) | (0.28) | -294.3% |
| DDM - Stable | 0.11 - 0.34 | 0.22 | 53.8% |
| DDM - Multi | (0.03) - (0.06) | (0.04) | -124.7% |
| Market Cap (mil) | 39.13 |
| Beta | 0.97 |
| Outstanding shares (mil) | 269.88 |
| Enterprise Value (mil) | 35.27 |
| Market risk premium | 4.74% |
| Cost of Equity | 8.39% |
| Cost of Debt | 4.25% |
| WACC | 7.73% |